1.
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and mo...
by Ducharme, Anique
The American heart journal, 2006, Vol.152 (1), p.86-92
2.
Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study
by O'Donnell, Martin J, Dr
The Lancet (British edition), 2016, Vol.388 (10046), p.761-775
3.
50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study
by Schnabel, Renate B, Dr
The Lancet (British edition), 2015, Vol.386 (9989), p.154-162
4.
A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial
by Vinereanu, Dragos
The Lancet (British edition), 2017-10-14, Vol.390 (10104), p.1737-1746
5.
Increasing Prevalence of Atrial Fibrillation and Flutter in the United States
by Naccarelli, Gerald V., MD
The American journal of cardiology, 2009, Vol.104 (11), p.1534-1539
6.
Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study
by Healey, Jeff S, Dr
The Lancet (British edition), 2016, Vol.388 (10050), p.1161-1169
7.
Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population
by Colilla, Susan, PhD, MPH
The American journal of cardiology, 2013, Vol.112 (8), p.1142-1147
8.
Probing oral anticoagulation in patients with atrial high rate episodes. Rationale and design of the Non vitamin K antagonist Oral anticoagulants in patients with Atrial High rate...
by Kirchhof, Paulus
The American heart journal, 2017, Vol.190, p.12-18
9.
Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation
by Camm, A John A John
Heart (British Cardiac Society), 2016-09-19, Vol.103 (4), p.307-314
10.
Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial
by Holmes, David R, Prof
The Lancet (British edition), 2009, Vol.374 (9689), p.534-542
11.
Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry
by Pokorney, Sean D., MD, MBA
The American heart journal, 2015, Vol.170 (1), p.141-148.e1
12.
13.
Meta-Analysis of Anxiety as a Risk Factor for Cardiovascular Disease
by Emdin, Connor A., HBSc
The American journal of cardiology, 2016, Vol.118 (4), p.511-519
14.
Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review
by Guttmann, Oliver P
Heart, 2014-03, Vol.100 (6), p.465-472
15.
Atrial fibrillation is associated with different levels of physical activity levels at different ages in men
by Drca, Nikola
Heart (British Cardiac Society), 2014-07, Vol.100 (13), p.1037-1042
16.
Do Patients Who Take Part in Stroke Research Differ from Non-Participants? Implications for Generalizability of Results
by Busija, Lucy
Cerebrovascular diseases (Basel, Switzerland), 2013-06, Vol.35 (5), p.483-491
17.
Meta-Analysis of Continuous Positive Airway Pressure as a Therapy of Atrial Fibrillation in Obstructive Sleep Apnea
by Qureshi, Waqas T., MD
The American journal of cardiology, 2015, Vol.116 (11), p.1767-1773
18.
Hypertension and Atrial Fibrillation: An Intimate Association of Epidemiology, Pathophysiology, and Outcomes
by Dzeshka, Mikhail S
American journal of hypertension, 2017-08-01, Vol.30 (8), p.733-755
19.
Subclinical thyroid disease
by Cooper, David S, Prof
The Lancet (British edition), 2012, Vol.379 (9821), p.1142-1154
20.
Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort
by Alonso, Alvaro
Heart (British Cardiac Society), 2014-10, Vol.100 (19), p.1511-1516
